Satellos Bioscience Inc.
MSLE · XNASCIK 1421642fmd_07FM38QEPEPT8P1T8KC1G7E8Q5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Dec 31, 2025, 2 periods
Latest annual · FY2025
Millions- Operating income
- (26)
- Net income
- (25)
- Free cash flow
- (24)
Daily close · MSLEIEX trades only
Mar 27, 2026 to Nov 11, 2026 · 137 sessions6.99 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Satellos Bioscience Inc. (MSLE) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$26.5 million | -$20.4 million | 40-F 2026-03-27 · proof | |
| Net income | -$24.9 million | -$20.6 million | 40-F 2026-03-27 · proof | |
| Cash from operating activities | -$23.6 million | -$18.3 million | 40-F 2026-03-27 · proof | |
| Free cash flow | -$23.6 million | -$18.3 million | 40-F 2026-03-27 · proof | |
| Total assets | $31.9 million | $50.7 million | -37.2% | 40-F 2026-03-27 · proof |
| Total liabilities | $4.1 million | $3.6 million | +14.6% | 40-F 2026-03-27 · proof |
| Cash and cash equivalents | $9.8 million | $40.1 million | -75.5% | 40-F 2026-03-27 · proof |
- What was Satellos Bioscience Inc. (MSLE)'s operating income in fiscal 2025?
- Satellos Bioscience Inc. (MSLE) reported operating income of -$26.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$20.4 million the year before. Source: the 40-F filed with the SEC on Mar 27, 2026. SEC
- What was Satellos Bioscience Inc. (MSLE)'s net income in fiscal 2025?
- Satellos Bioscience Inc. (MSLE) reported net income of -$24.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$20.6 million the year before. Source: the 40-F filed with the SEC on Mar 27, 2026. SEC
- What was Satellos Bioscience Inc. (MSLE)'s cash from operating activities in fiscal 2025?
- Satellos Bioscience Inc. (MSLE) reported cash from operating activities of -$23.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$18.3 million the year before. Source: the 40-F filed with the SEC on Mar 27, 2026. SEC
- What was Satellos Bioscience Inc. (MSLE)'s free cash flow in fiscal 2025?
- Satellos Bioscience Inc. (MSLE) reported free cash flow of -$23.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$18.3 million the year before. Source: the 40-F filed with the SEC on Mar 27, 2026. SEC
- What are Satellos Bioscience Inc. (MSLE)'s total assets?
- As of Dec 31, 2025, Satellos Bioscience Inc. (MSLE) reported total assets of $31.9 million, against $50.7 million a year earlier (-37.2%). Source: the 40-F filed with the SEC on Mar 27, 2026. SEC
- What are Satellos Bioscience Inc. (MSLE)'s total liabilities?
- As of Dec 31, 2025, Satellos Bioscience Inc. (MSLE) reported total liabilities of $4.1 million, against $3.6 million a year earlier (+14.6%). Source: the 40-F filed with the SEC on Mar 27, 2026. SEC
- What are Satellos Bioscience Inc. (MSLE)'s cash and cash equivalents?
- As of Dec 31, 2025, Satellos Bioscience Inc. (MSLE) reported cash and cash equivalents of $9.8 million, against $40.1 million a year earlier (-75.5%). Source: the 40-F filed with the SEC on Mar 27, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:MSLE&period_type=annual&limit=5"Information only, not investment advice.